Episode

Episode 400: Pharmacology 101: Radioimmunoconjugates

Podcast
The ONS Podcast
Published
Jan 30, 2026
Duration seconds
842
Processing state
not_requested
Canonical source
https://onsvoice.libsyn.com/episode-400-pharmacology-101-radioimmunoconjugates
Audio
https://traffic.libsyn.com/secure/onsvoice/400_Radioimmunoconjugates_mixdown.mp3?dest-id=557038
JSON
/v1/public/podcasts/the-ons-podcast-1126448/episodes/episode-400-pharmacology-101-radioimmunoconjugates
Markdown
/podcast/the-ons-podcast-1126448/episode-400-pharmacology-101-radioimmunoconjugates.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/the-ons-podcast-1126448/episodes/episode-400-pharmacology-101-radioimmunoconjugates/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/the-ons-podcast-1126448/episode-400-pharmacology-101-radioimmunoconjugates.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

"Radioimmunoconjugates work through a dual mechanism that combines immunologic targeting with localized radiation delivery. The monoclonal antibody components bind to specific tumor-associated antigens such as CD20, expressed on malignant B cells. Once found, the attached radioisotope delivers beta radiation directly to the tumor, causing DNA damage and cell death," Sabrina Enoch, MSN, RN, OCN ® , CNMT, NMTCB (CT), theranostics clinical specialist at Highlands Oncology in Rogers, AR, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS ® , manager of oncology nursing practice at ONS, during a conversation about radioimmunoconjugates. Music Credit: " Fireflies and Stardust " by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.25 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by January 30, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge in the history of, the mechanism of action of, and the use of radioimmunoconjugates in the treatment of cancer. Episode Notes Complete this evaluation for free NCPD . ONS Podcast ™ episodes: Pharmacology 101 series Episode 377: Creating and Implementing Radiopharmaceutical Policies and Procedures Episode 301: Radiation Oncology: Side Effect and Care Coordination Best Practices Episode 298: Radiation Oncology: Nursing's Essential Roles ONS Voice articles: Interprofessional Collaboration Reduces Time to Neutropenia Antibiotic Admin…